NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
TOP NEWS
»20/09/2009 [Industry news]
Genzyme Pushes to Expand Product Line in China

Genzyme Corp. (has begun building its $100 million R&D center in Beijing, according to an article in The China Daily. The center, which will eventually employ 350 people, will comprise 200,000 square feet (18,580 square meters) and is expected to be completed in 2011. It will seek to discover and develop novel biologics and other gene therapies.

 
Genzyme Corp. (has begun building its $100 million R&D center in Beijing, according to an article in The China Daily. The center, which will eventually employ 350 people, will comprise 200,000 square feet (18,580 square meters) and is expected to be completed in 2011. It will seek to discover and develop novel biologics and other gene therapies. The reasoning behind building the Beijing center is two-fold: China’s pool of scientists and the country’s huge market. The center will be tasked with finding drugs and therapies for diseases that are unique to China and the Far East. Citing company officials, the newspaper report also said Genzyme will be looking for acquisition candidates in China. At present, Genzyme offers three products in China. To push that number higher, the company has set a goal of having 20 products from five categories for sale in China within 10 years. Genzyme has expertise in oncology, kidney disease, osteoarthritis and metabolic diseases. It is the third largest biotech company in the world by revenue. The Beijing center will adhere to the US Green Building Council\'s Leadership in Energy and Environmental Design (LEED) rating system, the highest standard for energy efficiency.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.